US 12,268,730 B2
Use of a VEGF antagonist to treat angiogenic eye disorders
George D. Yancopoulos, Yorktown Heights, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Oct. 27, 2023, as Appl. No. 18/496,472.
Application 18/496,472 is a continuation of application No. 17/112,063, filed on Dec. 4, 2020.
Application 17/112,063 is a continuation of application No. 17/072,417, filed on Oct. 16, 2020.
Application 17/072,417 is a continuation of application No. 16/397,267, filed on Apr. 29, 2019, granted, now 10,888,601, issued on Jan. 12, 2021.
Application 16/397,267 is a continuation of application No. 16/159,282, filed on Oct. 12, 2018, granted, now 10,828,345, issued on Nov. 10, 2020.
Application 16/159,282 is a continuation of application No. 15/471,506, filed on Mar. 28, 2017, granted, now 10,130,681, issued on Nov. 20, 2018.
Application 15/471,506 is a continuation of application No. 14/972,560, filed on Dec. 17, 2015, granted, now 9,669,069, issued on Jun. 6, 2017.
Application 14/972,560 is a continuation of application No. 13/940,370, filed on Jul. 12, 2013, granted, now 9,254,338, issued on Feb. 9, 2016.
Application 13/940,370 is a continuation in part of application No. PCT/US2012/020855, filed on Jan. 11, 2012.
Claims priority of provisional application 61/561,957, filed on Nov. 21, 2011.
Claims priority of provisional application 61/434,836, filed on Jan. 21, 2011.
Claims priority of provisional application 61/432,245, filed on Jan. 13, 2011.
Prior Publication US 2024/0123030 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); C07K 14/71 (2006.01); C07K 16/22 (2006.01); C07K 19/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 38/179 (2013.01) [A61K 9/0048 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)] 30 Claims
 
1. A method for achieving in a patient in need thereof with an angiogenic eye disorder a gain in Best Corrected Visual Acuity (BCVA) of at least seven letters according to an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart within 52 weeks following an initial dose as compared to a baseline BCVA letter score, the method comprising:
measuring the baseline BCVA letter score of the patient,
administering to the patient a single initial dose of 2 mg of a VEGF antagonist by intravitreal injection, wherein the VEGF antagonist is a VEGF receptor-based chimeric molecule comprising (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO: 2; (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO: 2; and (3) a multimerization component comprising amino acids 232-457 of SEQ ID NO: 2,
administering to the patient one or more secondary doses of 2 mg of the VEGF antagonist by intravitreal injection approximately 4 weeks after the immediately preceding dose,
administering to the patient one or more tertiary doses of 2 mg of the VEGF antagonist by intravitreal injection approximately 8 weeks after the immediately preceding dose,
measuring BCVA of the patient at least once between the initial dose and 52 weeks following the initial dose, and
achieving in the patient a gain of at least seven letters of BCVA over the baseline BCVA according to the ETDRS visual acuity chart.